For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

FDA Peptide Regulatory Tracker (2026)

Research Library › Regulatory tracker

This tracker summarizes where each research peptide in the Kalibra Labs catalog stands with U.S. regulators as of 23 October 2026: FDA approval, FDA compounding lists, Pharmacy Compounding Advisory Committee (PCAC) votes and World Anti-Doping Agency (WADA) listing. It is updated when the FDA publishes a change.

Key 2026 developments

16 Apr 2026FDA announces removal of 12 peptides from its Category 2 compounding list, including BPC-157, TB-500, epitalon, GHK-Cu (injectable), LL-37, MOTS-c and PEG-MGF. Removal does not by itself permit compounding.[1]
23–24 Jul 2026PCAC votes on seven peptides for the 503A bulks list: six recommended, one (DSIP) not recommended. Votes are advisory.[2, 3]
14 Oct 2026FDA sends an interim access policy on compounding certain peptides to the White House Office of Information and Regulatory Affairs for review. Its text and peptide list are not public.[4]
By Feb 2027Next PCAC meeting scheduled to review LL-37, GHK-Cu, PEG-MGF, dihexa acetate and melanotan II.[5]

July 2026 PCAC votes

PeptideVoteRecommendation
BPC-1578–6 (1 abstain)For
TB-5008–6 (1 abstain)For
KPV8–6 (1 abstain)For
Semax8–5For
MOTS-c7–5 (2 abstain)For
Epitalon7–4 (1 abstain)For
DSIP (emideltide)6–7Against

No final FDA decision on any of these votes had been published as of 23 October 2026. Any change to the 503A bulks list requires notice-and-comment rulemaking.[3] Earlier, in December 2024, the PCAC voted 12–0 against AOD-9604 and 17–4 against thymosin alpha-1.[6]

Status by compound

5-Amino-1MQNot FDA-approved; not on FDA's 503A or 503B nomination lists or the Category 2 list
AdipotideNot FDA-approved; not approved elsewhere; phase 1 terminated 2019; development discontinued
AICARNot FDA-approved; not on FDA compounding nomination lists; WADA-prohibited (S4, AMPK activators)
AOD-9604Not FDA-approved; not approved elsewhere; PCAC voted 12–0 against 503A listing (Dec 2024); named on WADA 2026 list (S2)
ARA-290 (cibinetide)Not FDA-approved; FDA orphan designations 2011 and 2016; EU orphan designation 2013; FDA 503A Category 3
BPC-157Not FDA-approved; removed from FDA's Category 2 compounding list in April 2026; PCAC voted 8–6–1 in July 2026; no final FDA decision
CagrilintideNot FDA-approved; not approved elsewhere; CagriSema (with semaglutide) under FDA review, decision listed for Q4 2026
CardiogenNot FDA-approved; not on FDA's 503A, 503B or Category 2 lists
CartagenNot FDA-approved; not under FDA compounding review; Cartalax listed as a dietary supplement in Russia
CJC-1295Not approved anywhere; FDA compounding nomination withdrawn; named on WADA 2026 list (S2)
DSIPNot FDA-approved; FDA PCAC voted 6–7 against compounding eligibility in July 2026; no final FDA decision
EpitalonNot FDA-approved; PCAC voted 7-4 for compounding in July 2026; no final FDA decision
FOXO4-DRINot approved anywhere; no clinical trials listed; preclinical
GHK-CuNot FDA-approved as a drug; cosmetic ingredient in the U.S.; injectable form due for PCAC review by Feb 2027
GHRP-2Approved in Japan as a diagnostic (pralmorelin); not FDA-approved; FDA Category 2 since 2023; named on WADA 2026 list (S2)
GHRP-6Not FDA-approved; FDA Category 2 since 2023; named on WADA 2026 list (S2)
GonadorelinNo marketed FDA-approved human product; veterinary products approved; 503B Category 1 (under evaluation); WADA-prohibited in males
HexarelinNot FDA-approved; no approval identified elsewhere; named on WADA 2026 list (S2)
IGF-1 LR3Not approved as a drug anywhere; named on WADA 2026 list (S2)
IpamorelinNot approved anywhere; FDA Category 2 (503B) since 2023; named on WADA 2026 list (S2)
Kisspeptin-10Not approved anywhere; investigational; prohibited in males under WADA S2.2.1
KPVNot FDA-approved; PCAC voted 8–6–1 in July 2026; no final FDA decision
L-GlutathioneNo verified FDA drug approval; under FDA evaluation for 503A compounding
LL-37Not FDA-approved; removed from FDA Category 2 in April 2026 pending advisory review planned before end of February 2027
MGF (Mechano Growth Factor) and PEG-MGFNot FDA-approved; PEG-MGF removed from FDA Category 2 in April 2026, PCAC review due by Feb 2027; named on WADA 2026 list (S2)
MOTS-cNot FDA-approved; removed from Category 2 (Apr 2026); PCAC voted 7–5 for 503A listing (Jul 2026), no final decision; named on WADA 2026 list (S4)
NAD+Not FDA-approved as a drug; under FDA evaluation for 503A compounding
PE-22-28Not FDA-approved; not evaluated by FDA's compounding advisory committee
SelankNot FDA-approved; over-the-counter medicine in Russia; not reviewed by FDA's compounding advisory committee in 2026
SemaxNot FDA-approved; prescription medicine in Russia; PCAC voted 8–5 in favor of compounding eligibility in July 2026, no final FDA decision
SermorelinFormerly FDA-approved; discontinued 2008; FDA 2013: not withdrawn for safety or effectiveness; not on FDA Category 2 list; named on WADA 2026 list (S2)
SNAP-8Cosmetic ingredient; not approved as a drug anywhere
SS-31 (elamipretide)FDA accelerated approval (Forzinity, Sept 2025) for Barth syndrome only; not approved for any other use
TB-500Not FDA-approved; PCAC voted 8–6–1 on TB-500 compounding in July 2026; no final FDA decision
TesamorelinFDA-approved as Egrifta WR for a single HIV-related indication; EU application withdrawn 2012; named on WADA 2026 list (S2)
ThymalinRegistered in Russia (certificate dated 21 Jun 2024); not FDA-approved
Thymosin Alpha-1Not FDA-approved; approved in some countries, including China and Italy, as thymalfasin (Zadaxin)

Other compounds in the Research Library

Kalibra Labs does not supply the compounds below. They are covered as neutral reference pages because they appear widely in research-peptide catalogs and in current FDA actions.

CerebrolysinNot FDA-approved or registered in the US; registered in a number of European and Asian countries
DihexaNot FDA-approved; removed from Category 2 in April 2026; FDA PCAC review expected before end of February 2027, no date set
FollistatinNot FDA-approved or EMA-authorized in any form; listed by WADA under S4 as a myostatin-binding protein
LiraglutideFDA-approved as Victoza (2010) and Saxenda (2014); generic versions approved from Dec 2024; FDA proposed in April 2026 to exclude it from the 503B bulks list
MazdutideApproved in China (NMPA, June and September 2025); not FDA-approved; Phase II in Lilly studies outside China
Melanotan I (afamelanotide)Approved only as Scenesse (afamelanotide implant): EU 2014, FDA 2019, for erythropoietic protoporphyria; other "Melanotan I" products unapproved
Melanotan IINot FDA-approved; FDA enforcement against sale as an unapproved drug since 2007; removed from FDA Category 2 list April 2026; PCAC review scheduled before end of February 2027
OrforglipronFDA-approved as Foundayo (1 Apr 2026) for chronic weight management; a US application for type 2 diabetes was submitted in 2026 and not yet approved as of late Sept 2026
OxytocinFDA-approved prescription drug (Pitocin, NDA 018261) with labeled obstetric indications; boxed warning against elective induction of labor
PinealonNot FDA-approved; not EMA-authorized; not named individually on the 2026 WADA Prohibited List
PNC-27Not FDA-approved; no registered human clinical trial; preclinical only
PT-141 (bremelanotide)FDA-approved only as Vyleesi (June 2019); other "PT-141" products unapproved and named in FDA warning letters (Aug 2026)
RetatrutideNot FDA-approved; Phase 3 (TRIUMPH program) ongoing; Lilly plans US submission in Q1 2027; FDA says it cannot lawfully be compounded
SemaglutideFDA-approved in branded Novo Nordisk products; shortage resolved Feb 2025; FDA proposed in April 2026 to exclude it from the 503B bulks list; unapproved and "research use" versions subject to FDA warnings
SLU-PP-332Not FDA-approved; preclinical only; no registered human trial; not named individually on the 2026 WADA Prohibited List
SurvodutideNot FDA-approved; investigational, in Phase III trials (SYNCHRONIZE and LIVERAGE programs)
TesofensineNot FDA-approved or approved elsewhere; Medix application under review by COFEPRIS (Mexico) since February 2025 resubmission
TirzepatideFDA-approved as Mounjaro (2022) and Zepbound (2023); shortage resolved Dec 2024; FDA proposed in April 2026 to exclude it from the 503B bulks list; unapproved versions subject to FDA warnings
VIP (vasoactive intestinal peptide)Not FDA-approved; FDA compounding Category 1 (under evaluation, list updated May 2026); aviptadil combination product authorized in the UK and some European countries

How to read this tracker

  • FDA-approved means a specific drug product was approved for a labeled indication. It does not cover research-grade material.
  • Category 2 is FDA's list of nominated bulk substances that raise significant safety concerns for compounding.
  • 503A bulks list is the list of substances licensed pharmacies may use to compound. PCAC votes are recommendations to FDA, not decisions.
  • WADA status refers to the 2026 Prohibited List for sport.

Sources

  1. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 list. 16 Apr 2026. Link
  2. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  3. McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. 27 Jul 2026. Link
  4. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026. Link
  5. U.S. FDA. Meeting of the Pharmacy Compounding Advisory Committee (before end of February 2027). Link
  6. U.S. FDA. Pharmacy Compounding Advisory Committee, 4 Dec 2024: final summary minutes. Link

Last reviewed 23 October 2026 by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies lyophilized research materials for in-vitro laboratory use. They are not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page summarizes public regulatory records; it is not legal or medical advice.

Frequently asked questions

Which peptides did FDA remove from its Category 2 compounding list in April 2026?

On 16 April 2026 FDA announced the removal of 12 peptides from Category 2, including BPC-157, TB-500, epitalon, GHK-Cu (injectable), LL-37, MOTS-c and PEG-MGF. Removal does not by itself permit compounding.

How did the FDA advisory committee vote on peptides in July 2026?

On 23–24 July 2026 the Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides for the 503A bulks list. It recommended BPC-157 (8–6, 1 abstain), TB-500 (8–6, 1 abstain), KPV (8–6, 1 abstain), Semax (8–5), MOTS-c (7–5, 2 abstain) and epitalon (7–4, 1 abstain), and voted against DSIP (6–7).

Are PCAC votes binding on FDA?

No. PCAC votes are advisory. FDA makes the final decision, and any change to the 503A bulks list requires notice-and-comment rulemaking. No final FDA decision on the July 2026 votes had been published as of 23 October 2026.

Which compounds in the Kalibra catalog have FDA approval?

Two have FDA approval for a human indication: tesamorelin, approved as Egrifta WR for a single HIV-related indication, and SS-31 (elamipretide), which received accelerated approval as Forzinity in September 2025 for Barth syndrome only. Sermorelin was formerly approved and was discontinued in 2008, and gonadorelin is approved only in veterinary products. Kalibra supplies all compounds for laboratory research use only.

What happens next for peptide compounding policy?

On 14 October 2026 FDA sent an interim access policy on compounding certain peptides to the White House Office of Information and Regulatory Affairs for review; its text and peptide list are not public. The next PCAC meeting, scheduled by February 2027, is due to review LL-37, GHK-Cu, PEG-MGF, dihexa acetate and melanotan II.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top